Alkermes Plc (ALKS) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Alkermes Plc $47.62, price $42.13, upside +13.0%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Alkermes Plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $21.47 – $55.22 · fair‑value band $38.08 – $60.50 · the $42.13 price screens below the $47.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 4 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Alkermes in your weekly email
Every Wednesday you see whether Alkermes is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Show more
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Stock analysis
Alkermes Plc (ALKS) currently trades at $42.13, while our model-based Fair Value estimate is $47.62, implying the stock looks roughly 11.5% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $44.37 per share, and 8 of the 24 models we run sit above the $42.13 price.
Bear case: the Asset-Based group reads lowest at $7.31, and 16 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $38.08 (bear) to $60.50 (bull), the price of $42.13 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Alkermes Plc reported revenue of $1.5B in FY2025 versus $1.2B in FY2021, a compound +5.9%/yr. Reported net income was $242M in FY2025.
Key figures
Market cap $8.6B · P/E ratio 46.8 · P/S ratio 7.66 · EPS (TTM) $0.9000 · Net margin 16.4% · Return on equity 9.4% · Return on assets (EBIT) 10.9% · Operating margin −0.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 55% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 13%, ALKS screens cheaper than that median.
Fair Value models
Bear $38.08Fair Value $47.62Bull $60.50
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.6584 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Start year 2020 (pandemic). Over 10 years: +8.9% a year
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+3.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−11% → 17%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −4.0% a year for the price and +5.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside+13% · Above median
Profitability
Return on equity (TTM)9% · Above median
Return on assets5% · Above median
Net margin (TTM)10% · Above median
Operating margin (TTM)0% · Bottom 25%
Growth and dividend
Revenue growth28% · Top 25%
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Alkermes Plc Fair Value". https://www.fairvalue-calculator.com/stock/ALKS
Frequently asked questions
Is Alkermes Plc (ALKS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $47.62 versus a price of $42.13, about +13% upside (undervalued).
What is the fair value of ALKS?
Our model-based fair value for Alkermes Plc is $47.62 (as of Sep 24, 2026), built from audited fundamentals. The current price: $42.13.
What is the quality score of ALKS?
Alkermes Plc has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alkermes Plc (ALKS)?
Our model-based price target is the fair value of $47.62 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $38.08, optimistic scenario $60.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Alkermes Plc stock forecast for 2026?
Our models put fair value at $47.62, about +13% upside versus a price of $42.13 (undervalued). Cautious scenario $38.08, optimistic scenario $60.50. The calculation is refreshed regularly with new filings.
What is the revenue of Alkermes Plc (ALKS)?
Alkermes Plc reported trailing-twelve-month revenue of about $1.6B (latest available figure, as of Sep 24, 2026).
What growth is priced into Alkermes Plc (ALKS)?
For today's price to be fair in a discounted-cash-flow model, Alkermes Plc would have to grow free cash flow by -1.7 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of ALKS use?
Our models discount Alkermes Plc at 8.5 %: a base by market capitalisation (mid), damped by beta 0.29, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Alkermes Plc that is -1.7 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Alkermes Plc (ALKS) delivered so far?
Over the past 5 years revenue at Alkermes Plc grew +7.3 % a year. The price currently implies -1.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Alkermes Plc (ALKS) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Alkermes Plc (-1.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Alkermes Plc (ALKS)?
The free-cash-flow yield on the price is 6.76 %: that much free cash flow Alkermes Plc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Alkermes Plc (ALKS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alkermes Plc it is $47.62 per share (as of Sep 24, 2026), against a price of $42.13. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Alkermes Plc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ALKS trades below its calculated fair value: price $42.13, fair value $47.62, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALKS?
No. The price is what the market pays today ($42.13); the fair value is what the company's own numbers justify ($47.62). For Alkermes Plc the two are $5.49 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alkermes Plc worth?
The market values Alkermes Plc at about $8.6B (market capitalisation, as of Sep 24, 2026). Per share that is $42.13; our models calculate a fair value of $47.62 per share.
What do the bullish and bearish scenarios say about ALKS?
Our models span a range for Alkermes Plc: cautious scenario $38.08, base $47.62, optimistic $60.50 per share (as of Sep 24, 2026, price $42.13). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALKS?
Alkermes Plc trades at a price-to-earnings ratio of 46.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $47.62 is built from several models across several years. Other multiples: PEG 2.0, P/B 4.7, P/S 5.5, EV/EBITDA 27.9.
What is the PEG ratio of ALKS?
The PEG ratio of Alkermes Plc is 1.96 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Alkermes Plc (ALKS)?
Balance-sheet figures for Alkermes Plc (as of Sep 24, 2026): return on equity 9.4%, debt of 0.16 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is ALKS from its 52-week high?
Alkermes Plc trades at $42.13, about 24% below its 52-week high of $55.22 and 55% above the low of $27.13 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $47.62 is for.
Which stocks are comparable to Alkermes Plc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alkermes Plc stock attractive at the current price?
The data as of Sep 24, 2026: price $42.13, calculated fair value $47.62 (+13%), Quality Score 65/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALKS calculated?
We run Alkermes Plc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $47.62, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Alkermes Plc currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alkermes Plc (ALKS)?
The closing price on Sep 23, 2026 was $42.13. Our model-based fair value is $47.62, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alkermes Plc right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Alkermes Plc
How large is the market capitalisation of Alkermes Plc (ALKS)?
The market capitalisation of Alkermes Plc is $8.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Alkermes Plc (ALKS)?
The price-to-sales ratio of Alkermes Plc is 7.66 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Alkermes Plc (ALKS)?
Earnings per share at Alkermes Plc are $0.9000 (price ÷ EPS = P/E 46.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Alkermes Plc (ALKS)?
The net margin of Alkermes Plc is 16.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Alkermes Plc (ALKS)?
The return on equity (ROE) of Alkermes Plc is 9.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alkermes Plc (ALKS)?
On an EBIT basis the return on assets of Alkermes Plc is 10.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alkermes Plc (ALKS)?
The operating margin of Alkermes Plc is −0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alkermes Plc (ALKS)?
Revenue at Alkermes Plc is growing +28.2% versus a year earlier (3y avg +9.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Alkermes Plc (ALKS)?
Earnings per share at Alkermes Plc are growing −67.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Alkermes Plc (ALKS) hold?
Alkermes Plc holds more cash than debt, $1.0B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Alkermes Plc in the live analysis
One click puts Alkermes Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 24, 2026